Lipsitz, Ponterio & Comerford is now accepting cases on behalf of New York residents who believe they were harmed by GLP-1 medications such as Ozempic and Wegovy. Our firm has a long history of holding powerful corporations accountable when unsafe products cause real harm, and we are bringing that same approach to emerging pharmaceutical litigation. Across New York State, patients are coming forward with serious injuries they allege were caused by semaglutide-based medications including Ozempic, Wegovy, Saxenda and Trulicity. Many report that they were prescribed the drug for weight loss and were never warned about the risk of severe complications.
For decades, we have represented individuals and families harmed by corporate misconduct.
To date, our attorneys have recovered more than one billion dollars in settlements and verdicts for clients across New York.
Ozempic and GLP-1 medications are approved by the FDA for the treatment of Type 2 diabetes.
In recent years, it has been widely prescribed for weight loss, including for patients outside the populations studied in pre-approval clinical trials. As use expanded, reports of serious adverse effects followed.
Many lawsuits allege that patients were not adequately warned that GLP-1 medications can cause vision loss, specifically non-arteritic anterior ischemic optic neuropathy (NAION). NAION is a condition involving reduced blood flow to the optic nerve that can result in sudden, permanent vision loss. Patients allege they were never warned of a potential association between Ozempic and other GLP-1 drugs, rapid metabolic or blood pressure changes, and optic nerve injury, despite emerging reports and post-marketing safety signals.
At the core, these cases focus on failure-to-warn. Plaintiffs argue that manufacturers knew, or should have known, of the full scope of these risks based on clinical data, adverse event reports, and post-market surveillance, yet failed to provide clear, timely warnings to physicians and patients. The litigation centers on whether risk disclosures were inadequate, delayed, or minimized as off-label use of the drug for weight loss accelerated.
Pharmaceutical litigation is complex. It requires medical knowledge, scientific evidence, and the ability to challenge corporate conduct at scale. Lipsitz, Ponterio & Comerford has spent decades doing exactly that.
If you used Ozempic or another semaglutide medication and have been diagnosed with NAION you may have grounds to file a claim. Our attorneys are currently evaluating cases throughout New York State.
Patients have reported serious vision problems, including blurred vision, visual field loss, sudden vision loss, and non-arteritic anterior ischemic optic neuropathy (NAION). NAION occurs when blood flow to the optic nerve is reduced and can result in permanent vision damage or blindness.
Many lawsuits allege the risks of NAION injuries were not adequately disclosed before treatment began, preventing patients from making fully informed decisions.
Lipsitz, Ponterio & Comerford has spent decades standing up for people harmed by corporate negligence. Our commitment is rooted in the communities we serve and the families we represent.
If you have been diagnosed with NAION and used Ozempic or another GLP-1 medication, we are prepared to evaluate your case and explain your legal options under New York law.
We hope that you will never be diagnosed with mesothelioma, lung cancer, or suffer a catastrophic injury, but if you are, contact us at Lipsitz, Ponterio & Comerford so we can begin the fight.
Call Today: 866-238-1452 or fill out the online form.
Your state’s law may limit your time to file a legal claim. For a free and confidential case evaluation, please complete this form.
